

Supplemental Figure S9: Venetoclax enhances the efficacy of MRTX1133 in 2138-K and 1245-K tumors *in vivo*. 2138-K and 1245-K KPC cells ($2.5x10^4$) were implanted via subcutaneous injection into the flanks of C57BL/6 mice. Once animals developed ~80-100 mm^3 tumors, they were treated with vehicle control (C, DMSO), Venetoclax (V, 15mg/kg daily), MRTX1133 (M, 30mg/kg 2x/day), or the combination of Venetoclax and MRTX1133. **A, B.** 2138-K and 1245-K tumors at the study endpoints were stained for pERK, BIM, the proliferation marker Ki-67, and the apoptosis marker cleaved caspase 3 (c-C3). Error bars ± SD. One-way ANOVA, followed by Tukey's multiple comparison test. *, $p<0.05$; **, $p<0.01$; ***, $p<0.001$; ****, $p<0.0001$; ns, not significant.